Cell cycle and apoptosis machinery

The cell cycle and apoptosis machinery refers to the integrated network of regulatory proteins that control the progression of a cell through its division cycle and the initiation of programmed cell death (NIH, 2023: https://www.ncbi.nlm.nih.gov/books/NBK26869/). Central to the cell cycle are cyclin-dependent kinases (CDKs) and their regulatory cyclin subunits, which ensure orderly transition through G1, S, G2, and M phases. Conversely, apoptosis is governed by the BCL-2 family of proteins and the caspase cascade, which act as a safeguard to eliminate damaged or redundant cells (Nature Reviews Molecular Cell Biology, 2020: https://www.nature.com/articles/s41580-020-0231-2). Dysregulation of these processes is a hallmark of cancer, where overactive cell cycle drivers or suppressed apoptotic signals allow for unchecked tumor growth and survival (Cell, 2011: https://doi.org/10.1016/j.cell.2011.02.013). Pharmacological intervention targets these pathways using small molecules like CDK4/6 inhibitors (e.g., palbociclib) to induce cell cycle arrest or BCL-2 antagonists (e.g., venetoclax) to restore apoptotic sensitivity (Journal of Clinical Oncology, 2019: https://doi.org/10.1200/JCO.18.01422). While highly effective, targeting these fundamental biological processes often results in side effects such as myelosuppression due to the impact on rapidly dividing healthy cells (StatPearls, 2023: https://www.ncbi.nlm.nih.gov/books/NBK541072/). Modern oncology increasingly relies on biomarkers like p53 status or BCL-2 expression to tailor these therapies to specific patient populations.

Other names

Cell cycle regulatorsApoptotic signaling pathwaysProgrammed cell death machineryCell cycle control system

Inhibition of cyclin-dependent kinases (CDK4/6) to prevent G1-S phase transition; antagonism of BCL-2 anti-apoptotic proteins to trigger mitochondrial outer membrane permeabilization; stabilization of microtubules to induce mitotic arrest; inhibition of PARP to prevent DNA repair in cells with defective cell cycle checkpoints.